Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $345.95 | Total: $1,729.75 |
| 1 | 10 | $293.04 | Total: $2,930.40 |
| 1 | 25 | $248.27 | Total: $6,206.75 |
| 1 | 50 | $211.64 | Total: $10,582.00 |
| 1 | 100 | $183.15 | Total: $18,315.01 |
Overview
KCL-286 is an orally available and potent retinoic acid receptor beta agonist for the amelioration of spinal cord injury (SCI).
Chemical Properties
| Molecular Formula | C19H14N2O4 |
| Molecular Weight | 334.33 |
| CAS Numbers | 1952276-71-9 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C(O)C=1C=CC(=CC1)C2=NOC(=N2)C=3OC=4C(C3)=C(C=CC4C)C |
Storage and Handling
0C Short Term, -20C Long Term
References
Goncalves MB, et al. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-? agonist for treatment of spinal cord injury, in male healthy participants. Br J Clin Pharmacol. 2023 Jul 15.